PUBLIC COMPANY
save$ORICOric Pharmaceuticals, Inc.
$ORIC13.74-0.07%South San Francisco, CA, USupdated 3h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
- phase1Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- phase2Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- phase1Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
- phase1Effect of Food on the Pharmacokinetics of ORIC-114
- phase1Study of ORIC-101 in Combination With Enzalutamide
- phase1Study of ORIC-101 in Combination With Anticancer Therapy
Insider activity
source: SEC Form 4open-market buys + sells
- Feb 24, 26SELLPiscitelli Dominic· Chief Financial Officer−$703K↗
routine RSU / option mechanics (2)
- Feb 24, 26option exercisePiscitelli Dominic · Chief Financial Officer52,000 sh
- Feb 24, 26option exercisePiscitelli Dominic · Chief Financial Officer52,000 sh
🐶 Hiring Signal
News
- How Butterfly, once known for its handheld ultrasound device, is growing its chip-making businessNvidia got its start as a gaming chip maker before meteoric success selling its chips to nearly every industry. One health tech company is hoping to go down a similar route. Last month, ultrasound…endpoints · 1mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that